REFERENCES

1. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. *Nat Rev Dis Primers.* 2018;4:18010.

2. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PLOS ONE. 2019;https://doi.org/10.1371/journal.pone.0214355.

3. Centers for Disease Control and Prevention. Sickle Cell Disease (SCD) Data & Statistics. https://www.cdc.gov/ncbddd/sicklecell/data.html. Updated August 9, 2017. Accessed April 9, 2019.

4. Steinberg MH. Management of sickle cell disease. *N Engl J Med.* 1999;340(13):1021-1030.

5. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. *Lancet.* 2017;390(10091):311-323.

6. Wilkie DJ, Johnson B, Mack AK, Labotka R, Molokie RE. Sickle cell disease: an opportunity for palliative care across the life span. *Nurs Clin North Am.* 2010;45(3):375-397.

7. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: the PiSCES project. *Health Qual Life Outcomes.* 2005;3:50.

8. Yawn BP, John-Sowah J. Management of Sickle Cell Disease: Recommendations from the 2014 Expert Panel Report. *Am Fam Physician.* 2015;92(12):1069-1076.

9. Payne AB, Mehal JM, Chapman C, et al. Mortality trends and causes of death in persons with sickle cell disease in the United States, 1979-2014. *Blood.* 2014;130:865.

10. Brennan-Cook J, Bonnabeau E, Aponte R, Augustin C, Tanabe P. Barriers to care for persons with sickle cell disease: the case manager's opportunity to improve patient outcomes. *Prof Case Manag.* 2018;23(4):213-219.

11. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. *Lancet.* 2010;376(9757):2018-2031.

12. Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. *Blood Rev.* 2013;27(6):279-287.

13. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. *J Clin Invest.* 2017;127(3):750-760.

14. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. *J Clin Invest.* 2000;106(3):411-420.

15. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. *N Engl J Med.* 2004;350(9):886-895.

16. Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. *Am J Med.* 1997;102(2):171-177.

17. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. *Am J Hematol.* 2009;84(9):618-625.

18. Sins JWR, Mager DJ, Davis S, Biemond BJ, Fijnvandraat K. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. *Blood Adv.* 2017;1(19):1598-1616.

19. Smith WR, Scherer M. Sickle-cell pain: advances in epidemiology and etiology. *Hematology Am Soc Hematol Educ Program.* 2010;2010:409-415.

20. Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. *JAMA.* 2010;303(18):1823-1831.

21. DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. *Blood.* 2012;119(20):4587-4596.

22. Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality. *Br J Haematol.* 2017;178(2):319-326.

23. Shet AS, Wun T. How I diagnose and treat venous thromboembolism in sickle cell disease. *Blood.* 2018;132(17):1761-1769.

24. Brousse V, Elie C, Benkerrou M, et al. Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients. *Br J Haematol.* 2012;156(5):643-648.

25. Ngo S, Bartolucci P, Lobo D, et al. Causes of death in sickle cell disease adult patients: old and new trends. *Blood.* 2014;124:2715.

26. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? *Curr Opin Hematol.* 2011;18(3):158-165.

27. DROXIA (hydroxyurea capsules) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company. 2012.

28. Kapoor S, Little JA, Pecker LH. Advances in the treatment of sickle cell disease. *Mayo Clin Proc.* 2018;93(12):1810-1824.

29. Endari (L-glutamine oral powder) [prescribing information]. Torrance, CA: Emmaus Medical Inc. 2017.

30. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. *N Engl J Med.* 2018;379(3):226-235.

31. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. *Haematologica.* 2011;96(6):801-807.

32. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. *Arch Intern Med.* 1988;148(11):2485-2489.

33. Oksenberg D, Dufu K, Patel MP, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. *Br J Haematol.* 2016;175(1):141-153.

34. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. *N Engl J Med.* 2019;381(6):509-519.

35. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. *Am J Hematol.* 2019;94(1):55-61.

36. Masese RV, Bulgin D, Douglas C, Shah N, Tanabe P. Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: the emergency department providers' perspective. *PLoS One.* 2019;14(5):e0216414.

37. Hudon C, Chouinard MC, Diadiou F, Lambert M, Bouliane D. Case management in primary care for frequent users of health care services with chronic diseases: a qualitative study of patient and family experience. *Ann Fam Med.* 2015;13(6):523-528.